Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IRMD
BUYFLAGIRADIMED CORPORATION · Healthcare · United States · $1.2B · Avg Vol: $13M/d
IRADIMED has exceptional quality Q91 and momentum M64, but value at V19 is among the lowest in this run and far below the calibrated floor, and insiders sold, so stage one fails.
COMPANY DESCRIPTION
IRADIMED CORPORATION is a pioneer and market leader in the development of non-magnetic intravenous (IV) infusion pumps and patient monitoring systems designed for use in MRI environments. The company's competitive moat is its proprietary, non-magnetic technology, which eliminates the safety hazards of standard medical devices near powerful MRI magnets. It operates as a highly specialized, high-margin medical device manufacturer with a near-monopoly in its niche.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.3M | 65.6M | 73.2M | 83.8M | 16.3% | 86.3M | 91.2M | 100.9M | 9.7% |
| EPS | 1.02 | 1.36 | 1.52 | 1.77 | 20.2% | 1.83 | 1.90 | 2.16 | 10.5% |
| Shares | 12.6M | 12.7M | 12.7M | 12.8M | +1.5% | 12.8M | — | — | — |
| Debt | 2.2M | 2.0M | 2.0K | 0 | -97.0% | — | — | — | — |
| Equity | 73.7M | 71.4M | 86.8M | 94.6M | 8.7% | — | — | — | — |
| Op CF | 10.0M | 13.5M | 25.6M | 24.9M | 35.4% | 28.9M | — | — | — |
| Inv CF | -1.4M | -8.0M | -8.8M | -8.4M | — | — | — | — | — |
| Fin CF | -12.7M | -13.7M | -14.3M | -17.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IRMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IRMD | IRADIMED CORPORATION(you) | $1.2B | 78 | BUY |
| AHCO | AdaptHealth Corp. | $1.5B | 79 | BUY |
| IART | Integra LifeSciences Holdings Corporation | $1.5B | 80 | BUY |
| ENOV | Enovis Corporation | $1.6B | 80 | BUY |
| AVNS | Avanos Medical, Inc. | $1.2B | 72 | BUY |
| CNMD | CONMED Corporation | $1.3B | 86 | STRONG BUY |
| UFPT | UFP Technologies, Inc. | $1.8B | 75 | BUY |
| TCMD | Tactile Systems Technology, Inc. | $620M | 87 | STRONG BUY |
| DCTH | Delcath Systems, Inc. | $422M | 76 | BUY |
| BVS | Bioventus Inc. | $799M | 96 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%